Redbiotec is one of the partners that were granted the Edufluvac project in the frame of the EU FP7- package. The EU contribution is EUR4.6 million.
The project aims towards "universal" influenza vaccines, providing longer-lasting and broader protection against multiple strains of the virus, ultimately protecting the general population from seasonal and pandemic influenza.
Redbiotec’s technology platform rePAX will be applied to generate a large number of multivalent vaccine candidates. The efficiency of the platform with respect to fast manufacturing of complex Virus-like Particles, and the scalability of the manufacturing process were the criteria for the selection of Redbiotec in this prestigious program.
“Redbiotec is proud to be part of this consortium, a significant validation of its achievements and proof of trust into its technology platform by external specialists”, writes the company in its newsletter.
Please login or sign up to comment.
Commenting guidelines